scholarly journals Acute psychotic disorders induced by topiramate: report of two cases

2002 ◽  
Vol 60 (2A) ◽  
pp. 285-287 ◽  
Author(s):  
Florindo Stella ◽  
Dorgival Caetano ◽  
Fernando Cendes ◽  
Carlos A.M. Guerreiro

We report on two epileptic patients who developed acute psychosis after the use of topiramate (TPM). One patient exhibited severe psychomotor agitation, heteroaggressiveness, auditory and visual hallucinations as well as severe paranoid and mystic delusions. The other patient had psychomotor agitation, depersonalization, derealization, severe anxiety and deluded that he was losing his memory. Both patients had to be taken to the casualty room. After interruption of TPM in one patient and reduction of dose in the other, a full remission of the psychotic symptoms was obtained without the need of antipsychotic drugs. Clinicians should be aware of the possibility of development of acute psychotic symptoms in patients undergoing TPM treatment.

2002 ◽  
Vol 8 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Walter Pierre Bouman ◽  
Gill Pinner

Antipsychotic drugs are among the most widely prescribed psychotropic medications for elderly people, particularly for the 5–8% of patients who are in institutions. The antipsychotics are indicated for treating psychotic disorders, including schizophrenia, delusional disorder, psychotic symptoms in mood disorders and for a number of organic psychoses.


2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Gene Chibuchim Otuonye ◽  
Otto Gibbs ◽  
Rani Delraj Sittol ◽  
Matthew V Tavares ◽  
Munder Abuaisha ◽  
...  

Abstract Introduction The neurogenic response to hypoglycemia (HG) is well established. In contrast, neuroglycopenic (NG) manifestations are widely variable and have been erroneously attributed to other diagnoses. Compounding diagnostic uncertainty is the incidence of these symptoms in a patient with a psychiatric illness. Clinical Case A 51 year old male with hypertension and schizophrenia maintained on amlodipine, risperidone and benztropine was transported to the ER psychiatric unit by law enforcement. He was detained after he was found wandering the streets demonstrating increased verbal and physical aggressiveness. He was known to the unit, with previous admissions for psychosis secondary to schizophrenia. On presentation vitals were solely significant for tachycardia. Physical and mental status examination revealed a disheveled, agitated and combative male who was disoriented to time, person and location. He was actively experiencing visual and auditory hallucinations with psychomotor agitation, intermittent loosening of association, circumstantial speech and persecutory delusions. Initially given one dose of i.m. haloperidol and benztropine, his psychosis persisted. Biochemical investigations were significant for a glucose of 37 mg/dL; All others including alcohol level, toxicology and TSH were normal. Head CT was unremarkable. His HG was treated with i.v. dextrose with complete resolution of psychotic symptoms within one hour of normoglycemia. He needed no further antipsychotic doses save his maintenance risperidone. Further historical enquiry revealed a recent diagnosis of type 2 DM managed on metformin and glimepiride with poor oral intake. He was discharged on metformin and sitagliptin post extensive DM self-management education, h; glimepiride was discontinued. Discussion NG manifestations of hypoglycemia are the direct result of central nervous system glucose deprivation. Uncommonly, they can be the sole presenting complaint in the HG patient. In one study, 27% of patients with insulinomas had only NG symptoms [1]. Interestingly, some case reports suggest acute psychosis may be an important NG feature [2]. Psychiatric patients, particularly those with primary psychotic disorders often face a labyrinthine process when seeking emergent medical care including but not limited to anchoring and ascertainment physician bias. If unrecognized, HG can lead to neuronal death. Clinicians must maintain a high index of suspicion of HG in patients presenting with acute psychosis even in the presence of functional illness so as to reduce morbidity, mortality and medicolegal risk. References Dizon AM., Kowalyk S., Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas, Am J Med. 1999 Mar; 106(3):307-10. Klemen P., Grmec S., Cander, D. Hypoglycemia masquerading as acute psychosis in young age. Crit Care. 2000; 4(Suppl 1): P172. doi: 10.1186/cc892.


GeroPsych ◽  
2013 ◽  
Vol 26 (4) ◽  
pp. 205-209 ◽  
Author(s):  
Ali Javadpour ◽  
Maryam Sehatpour ◽  
Arash Mani ◽  
Ali Sahraian

Background: There are many controversies with regard to the nosology and conditions causing psychosis in old age people. This study defines a symptom profile and differential diagnosis of late-onset psychosis. Method: 201 elderly persons with psychotic symptoms were recruited. All patients were interviewed based on SCID-1 to confirm the possible diagnosis. Results: The most delusional symptom reported by the subjects was persecutory delusion, and visual hallucinations were the most common hallucination. The most repeated diagnosis was dementia, followed by psychosis due to mood disorders, primary psychotic disorders, delirium, and psychosis due to medical conditions. Conclusions: Results from the current study indicate that late-life psychoses form a heterogeneous group of disorders with varying symptom profiles and etiologies.


Author(s):  
Kimberley Kendall ◽  
Jeremy Hall ◽  
Michael Owen

In this chapter the occurrence of schizophrenia, other psychotic disorders, psychotic symptoms in intellectual disability, and autism spectrum disorder is considered, as are the similarities in clinical features between these disorders. Also reviewed are the evidence for genetic overlaps between these disorders and their convergence on specific biological pathways. Finally, the evidence for overlap in environmental risk factors between these disorders is considered. Taken together these findings suggest that schizophrenia and the other functional psychoses may be related aetiologically and pathogenically with the group of neurodevelopmental disorders to which intellectual disability and autism belong. Indeed these disorders might be better conceptualized as lying on a spectrum of clinical outcomes that result from disruption to the developing brain induced by genetic and environmental factors. The chapter concludes with a discussion of the clinical implications of these findings.


2020 ◽  
pp. 487-495
Author(s):  
Stefan Leucht ◽  
Andrea Cipriani ◽  
Toshi A. Furukawa

Antipsychotic drugs should be efficacious for all psychotic symptoms, whether they occur in schizophrenia, depression, mania, or any other psychotic disorder. All currently marketed antipsychotic drugs are dopamine antagonists or partial agonists, making the role of dopamine blockade in this context the most likely mechanism of action. Antipsychotics show efficacy in treatment and in maintenance across the common psychosis diagnoses, especially when looking across large metanalyses. Yet, there is an important imbalance as to how well the pharmacological treatment of the different psychotic disorders have been addressed in the literature, with schizophrenia being predominant.


2017 ◽  
Vol 41 (S1) ◽  
pp. S650-S650
Author(s):  
A. Fontaine ◽  
G. Radu

IntroductionWith 10 million of patients across the world, Parkinson's disease is the second most common form of neurodegeneration, after Alzheimer's. Among half of patients develop psychotic symptoms, such as visual hallucinations and delusions, which are correlated with higher rate of placement in nursing home, are difficult to treat and severely affect quality of life, making Parkinson's disease psychosis (PDP) a major public health issue.ObjectivesThe aim of this study is to identify treatment options that could be used to treat PDP and clarify underlying pathophysiology.MethodWe conducted a literature review on Pubmed, Goggle scholar and Cochrane library, using a combination of the following: “Parkinson's disease Psychosis” “visual hallucinations” “Pimavanserin” “Clozapine” “atypical anti-psychotics” 120 articles were screened.ResultsConsidering that hallucinations arise from overactivation of dopaminergic receptors, treatment options include reducing the dopaminergic drugs used to control motor symptoms; using atypical anti-psychotics such as Risperidone, Olanzapine, Quetiapine, which often results in the worsening of extra-pyramidal symptoms. Another option is the use of low doses of Clozapine, which has been proven efficient with no worsening of non-motor symptoms, suggesting the implication of other pathways, such as serotonin. Finally, Pimavanserin, a 5-HT2A receptor inverse agonist, without any dopaminergic activity, has been demonstrated to be effective in the treatment of PDP, well tolerated and easy to use.ConclusionSerotonin inverse agonists represent a major breakthrough in the pharmacotherapy of PDP, and may lead the way to changes in the treatment of schizophrenia and other psychotic disorders.Disclosure of interestThe authors have not supplied their declaration of competing interest.


2020 ◽  
Vol 26 ◽  
Author(s):  
Felix-Martin Werner ◽  
Rafael Coveñas

Background: Schizophrenia and schizoaffective disorder are treated with antipsychotic drugs. Some patients show treatment-resistant forms of psychotic disorders and, in this case, they can be treated with clozapine. In these patients and based on previous reviews on novel antipsychotic drugs, it is important to know whether an add-on therapy with new drugs can ameliorate the positive and negative schizophrenic scale (PANSS) total score. Objective: The aim of this review is to suggest an appropriate treatment for patients with treatment-resistant forms of psychotic disorders. A combination of current available antipsychotic drugs with novel antipsychotic or modulating drugs might improve negative schizophrenic symptoms and cognitive function and thereby social functioning and quality of life. Results: The mechanisms of action, the therapeutic effects and the pharmacokinetic profiles of novel antipsychotic drugs such as cariprazine, brexipiprazole and lumateperone are up-dated. Published case reports of patients with treatmentresistant psychoses are also discussed. These patients were treated with clozapine but a high PANSS total score was observed. Only an add-on therapy with cariprazine improved the score and, above all, negative schizophrenic symptoms and cognitive functions. To ensure a constant antipsychotic drug concentration, long-acting injectable antipsychotic drugs may be a choice for a maintenance therapy in schizophrenia. New modulating drugs, such as receptor positive allosteric modulators (N-methyl-D-aspartate receptor; subtype 5 of the metabotropic glutamatergic receptor) and encenicline, an alpha7 nicotinic cholinergic receptor agonist, are being investigated in preclinical and clinical trials. Conclusion: In clinical trials, patients with treatment-resistant forms of psychosis should be examined to know whether a combination therapy with clozapine and a novel antipsychotic drug can ameliorate the PANSS total score. In schizophrenia, long-acting injectable antipsychotic drugs are a safe and tolerable maintenance therapy. In further clinical studies, it should be investigated whether patients with treatment-resistant forms of psychoses can improve negative schizophrenic symptoms and cognitive functions by an add-on therapy with cognition enhancing drugs.


Author(s):  
Brandon Gunasekera ◽  
Kelly Diederen ◽  
Sagnik Bhattacharyya

Abstract Background Evidence suggests that an overlap exists between the neurobiology of psychotic disorders and the effects of cannabinoids on neurocognitive and neurochemical substrates involved in reward processing. Aims We investigate whether the psychotomimetic effects of delta-9-tetrahydrocannabinol (THC) and the antipsychotic potential of cannabidiol (CBD) are underpinned by their effects on the reward system and dopamine. Methods This narrative review focuses on the overlap between altered dopamine signalling and reward processing induced by cannabinoids, pre-clinically and in humans. A systematic search was conducted of acute cannabinoid drug-challenge studies using neuroimaging in healthy subjects and those with psychosis Results There is evidence of increased striatal presynaptic dopamine synthesis and release in psychosis, as well as abnormal engagement of the striatum during reward processing. Although, acute THC challenges have elicited a modest effect on striatal dopamine, cannabis users generally indicate impaired presynaptic dopaminergic function. Functional MRI studies have identified that a single dose of THC may modulate regions involved in reward and salience processing such as the striatum, midbrain, insular, and anterior cingulate, with some effects correlating with the severity of THC-induced psychotic symptoms. CBD may modulate brain regions involved in reward/salience processing in an opposite direction to that of THC. Conclusions There is evidence to suggest modulation of reward processing and its neural substrates by THC and CBD. Whether such effects underlie the psychotomimetic/antipsychotic effects of these cannabinoids remains unclear. Future research should address these unanswered questions to understand the relationship between endocannabinoid dysfunction, reward processing abnormalities, and psychosis.


2021 ◽  
pp. 025371762199953
Author(s):  
Bhavneesh Saini ◽  
Pir Dutt Bansal ◽  
Mamta Bahetra ◽  
Arvind Sharma ◽  
Priyanka Bansal ◽  
...  

Background: Normal personality development, gone awry due to genetic or environmental factors, results in personality disorders (PD). These often coexist with other psychiatric disorders, affecting their outcome adversely. Considering the heterogeneity of data, more research is warranted. Methods: This was a cross-sectional study on personality traits in psychiatric patients of a tertiary hospital, over 1 year. Five hundred and twenty-five subjects, aged 18–45 years, with substance, psychotic, mood, or neurotic disorders were selected by convenience sampling. They were evaluated for illness-related variables using psychiatric pro forma; diagnostic confirmation and severity assessment were done using ICD-10 criteria and suitable scales. Personality assessment was done using the International Personality Disorder Examination after achieving remission. Results: Prevalence of PD traits and PDs was 56.3% and 4.2%, respectively. While mood disorders were the diagnostic group with the highest prevalence of PD traits, it was neurotic disorders for PDs. Patients with PD traits had a past psychiatric history and upper middle socioeconomic status (SES); patients with PDs were urban and unmarried. Both had a lower age of onset of psychiatric illness. Psychotic patients with PD traits had higher and lower PANSS positive and negative scores, respectively. The severity of personality pathology was highest for mixed cluster and among neurotic patients. Clusterwise prevalence was cluster C > B > mixed > A (47.1%, 25.2%, 16.7%, and 11.4%). Among subtypes, anankastic (18.1%) and mixed (16.7%) had the highest prevalence. Those in the cluster A group were the least educated and with lower SES than others. Conclusions: PD traits were present among 56.3% of the patients, and they had many significant sociodemographic and illness-related differences from those without PD traits. Cluster C had the highest prevalence. Among patients with psychotic disorders, those with PD traits had higher severity of psychotic symptoms.


PLoS ONE ◽  
2015 ◽  
Vol 10 (6) ◽  
pp. e0125103 ◽  
Author(s):  
Marije Swets ◽  
Frank Van Dael ◽  
Sabine Roza ◽  
Robert Schoevers ◽  
Inez Myin-Germeys ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document